The possibility that infectious agents may trigger a cascade of reactions leading to inflammation, atherogenesis, and vascular thrombotic events has recently been raised. Chlamydia pneumoniae is one of those that have received the most investigative attention with respect to coronary artery disease (CAD). This study was undertaken for the first time in Shiraz, Iran to determine this relationship. A case-control study was conducted in 167 subjects (81 women and 86 men) who underwent coronary angiography at cardiac catheterization laboratories of Shiraz University of Medical Sciences Hospitals. Immunoglobulin G (IgG), and IgA antibodies to C. pneumoniae antigen were estimated in baseline serum samples from 109 patients (mean age 57 years) experiencing a coronary event and from their matched controls (n=58, mean age 50 years) by ELISA method. The prevalence of IgG and IgA antibodies to C. pneumoniae did not show any case-control differences (82.6% vs 74.1% and 22% vs 15.5%, respectively). These results suggest that although C. pneumoniae was highly prevalent among these patients, it did not appear to be associated with angiographically documented CAD and cannot be regarded as a positive predictor for the development of acute coronary syndrome.
Get full access to this article
View all access options for this article.
References
1.
Biasucci LM, Liuzzo G, Grillo RL, et al: Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation99:855-860, 1999.
2.
Haverkate F, Thompson SG, Pyke SDM, et al: Production of C-reactive and risk of coronary events in stable and unstable angina. Lancet349:462-466, 1997.
3.
Mendall MA, Patal P, Ballam L, et al: C-reactive protein and its relation to cardiovascular risk factors: A population-based cross-sectional study. BMJ312:1061-1065, 1996.
4.
Anderson JL, Carlquist JF, Muhlestein JB, et al: Evaluation of C-reactive protein and inflammatory markers, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol32:35-41, 1998.
5.
Becker AE, de-Boer OJ, Vander Wal AC: The role of inflammation and infection in coronary artery disease. Annu Rev Med52:289-297, 2001.
6.
Davidson M, Kuo CC, Middaugh JP, et al: Confirmed previous infection with C. pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation98:628-633, 1998.
7.
Gurfinkel E: Inflammation, infection, or both in atherosclerosis: The ROXIS trial in prospective. J Infect Dis181(suppl 3):S566-S568, 2000.
8.
Kaski JC, Camm AJ: C. pneumoniae infection and coronary artery disease. J Am Coll Cardiol34:1440-1442, 1999.
9.
Leinone M: C. pneumoniae and other risk factors for atherosclerosis. J Infect Dis181(suppl 3):S414-S416, 2000.
10.
Mehta JL, Saldeen TGP, Rand K: Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol31:1217-1225, 1998.
11.
Muhlestein JB, Hammond EH, Carlquist JF, et al: Increased incidence of Chlamydiaspecies within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol27:1555-1561, 1996.
12.
Sessa R, Di Pietro M, Santino I, et al: C. pneumoniaeinfection and atherosclerotic coronary disease. Am Heart J137:1116-1119, 1999.
13.
Smith D, Gupta S, Kaski JC: Chronic infection and coronary heart disease (review). Int J Clin Pract53:460-466, 1999.
14.
Zhu J, Nieto FJ, Horne BD, et al: Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation103:45-51, 2001.
15.
Daus H, Ozbek C, Saage D, et al: Lack of evidence for a pathogenic role of C. pneumoniae and cytomegalovirus infection in coronary atheroma formation. Cardiology90:83-88, 1998.
16.
Saikku P: Epidemiologic association of C. pneumoniae and atherosclerosis: The initial serologic observation and more. J Infect Dis181(suppl 3):S411-S413, 2000.
17.
Tavandale R, Parratt D, Pringle SD, et al: Serological markers of C. pneumoniae infection in men and women and subsequent coronary events. Eur Heart J23:301-307, 2002.
18.
Tsai CT, Kao JH, Hsu KL, et al: Relation of C. pneumoniae infection in Taiwan to angiographically demonstrated coronary artery disease and to the presence of acute myocardial infarction of unstable angina pectoris. Am J Cardiol88:960-963, 2001.
19.
Saikko P, Linonen M, Tenkanen L, et al: Chronic C. pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Int Med116:273-278, 1992.
20.
Thom DH, Grayston JT, Siscovick DS, et al: Association of prior infection with C. pneumoniae and angiographically demonstrated coronary artery disease. JAMA268:68-72, 1992.
21.
Shimada K, Daida H, Molcumo H, et al: Association of seropositivity for antibody to Chlamydia-specific lipopolysaccharide and coronary artery disease in Japanese men. Jpn Circ J65:182-187, 2001.
22.
Thom DH, Wang SP, Grayston T, et al: C. pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb Vasc Biol11:547-551, 1991.
23.
Ridker PM, Hennekens CH, Buring JE, et al: Baseline IgG antibody titers to C. pneumoniae, H. pylori,herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med131:573-577, 1999.
24.
Wald NJ, Law MR, Morris JK, et al: C. pneumoniaeinfection and mortality from ischemic heart disease: Large prospective study. BMJ321:204-207, 2000.
25.
Maas M, Bartales C, Engel PM, et al: Endovascular presence of viable C. pneumoniae as a common phenomenon in coronary artery disease. Am J Coll Cardiol31:827-832, 1998.
26.
Wong YK, Dawkins KD, Ward ME: Circulating C. pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol34:1435-1439, 1999.
27.
Nieto FJ, Folsom AR, Sorlie PD, et al, for the atherosclerosis risk in communities (ARIC) study investigators: C. pneumoniae infection and incident coronary heart disease. The atherosclerosis risk in communities study. Am J Epidemiol150:149-156, 1999.
28.
Strachan DP, Carvington D, Mendall MA, et al: Relation of C. pneumoniae serology to mortality and incidence of ischemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ318:1035-1050, 1999.
29.
Danesh J, Whincup P, Walker M, et al: C. pneumoniae IgG titers and coronary heart disease; prospective study and meta-analysis. BMJ321:208-213, 2000.
30.
Thomas M, Wong Y, Thomas D, et al: Relation between direct detection of C. pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque. Circulation99:2733-2736, 1999.
31.
Karvonen M, Tuomilehto J, Pitlcaniemi J, et al: C. pneumoniae IgG antibody prevalence in southwestern and eastern Finland in 1982 and 1987. Int J Epidemiol23:176-184, 1994.
32.
Murray LJ, O’Reilly DPJ, Ong GML, et al: C. pneumoniae antibodies are associated with an atherogenic lipid profile. Heart81:239-244, 1999.
